2026

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noreferrer noopener" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div> <iframe src="https://tokenist.outseta.com/forms/yWorZM9D" width="100%" height="800" frameborder="0"></iframe> 
<p class="has-drop-cap">Abbott Laboratories faced a sharp selloff on January 22, 2026, as shares plunged over 7% in <a href="https://tokenist.com/investing/how-to-trade-after-hours/" rel="dofollow" class="deco-link">premarket trading</a> despite meeting <a href="https://abbott.mediaroom.com/2026-01-22-Abbott-Reports-Fourth-Quarter-and-Full-Year-2025-Results-Issues-2026-Financial-Outlook" target="_blank" aria-label="fourth-quarter earnings (opens in a new tab)" rel="noreferrer noopener nofollow" class="deco-link">fourth-quarter earnings</a> expectations. The healthcare giant’s revenue miss and disappointing first-quarter guidance overshadowed its solid earnings performance, triggering investor concerns about near-term growth prospects.</p> 
<p>The company reported adjusted earnings per share of $1.50, matching analyst estimates, but revenue of $11.46 billion fell short of the $11.8 billion consensus, marking a concerning gap that weighed heavily on market sentiment.</p> 
<h3 id="abbott-delivers-solid-eps-but-revenue-miss-weighs-on-the-report">Abbott Delivers Solid EPS, But Revenue Miss Weighs on the Report</h3> 
<p>Abbott’s fourth-quarter results painted a picture of uneven performance across its business segments. While the company achieved adjusted <a href="https://tokenist.com/investing/how-to-value-a-stock/" rel="dofollow" class="deco-link">EPS</a> of $1.50, meeting analyst expectations, total sales of $11.46 billion came in roughly $340 million below consensus forecasts. The company posted total sales growth of 4.4% on a reported basis and 3.0% organically, though organic growth excluding COVID-19 testing-related sales reached 3.8% year-over-year.</p> 
<p>The Medical Devices segment emerged as the standout performer, delivering sales of $5.68 billion with growth of 12.3% on a reported basis. Diabetes Care, which includes the company’s continuous glucose monitoring products, showed particular strength with sales climbing 14.5% to $2.13 billion. However, these gains were offset by significant weakness in other divisions.</p> 
<p>Nutrition sales declined sharply by 8.9% to $1.94 billion, which Abbott attributed to lower sales volumes and strategic pricing actions designed to stimulate future demand. The Diagnostics segment also disappointed, with sales falling 2.5% to $2.46 billion, hampered by reduced demand for COVID-19 testing products that had previously boosted results.</p> 
<div class="cta-referral"> 
 <img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async"> 
 <div class="cta-referral__text"> 
  <p>Join our <a href="https://t.me/thetokenist" target="_blank" rel="nofollow">Telegram group</a> and never miss a breaking digital asset story.</p> 
 </div> 
</div> 
<h3 id="investor-focus-shifts-to-2026-outlook-after-post-earnings-selloff">Investor Focus Shifts to 2026 Outlook After Post-Earnings Selloff</h3> 
<p>The market’s negative reaction intensified following Abbott’s first-quarter 2026 guidance, which came in materially below Street expectations. The company projected adjusted EPS of $1.12 to $1.18 for the first quarter, falling short of the analyst consensus of $1.20. This guidance miss suggested near-term headwinds that could persist beyond the fourth-quarter weakness.</p> 
<p>Despite the disappointing near-term outlook, Abbott issued full-year 2026 guidance that exceeded expectations. The company forecasts organic sales growth of 6.5% to 7.5% and adjusted EPS of $5.55 to $5.80, surpassing the analyst consensus of $5.17 and representing approximately 10% growth at the midpoint. Chairman and CEO Robert B. Ford expressed confidence in the company’s positioning, stating that Abbott achieved double-digit earnings per share growth in 2025 while expanding margins and advancing its product pipeline.</p> 
<p>At the market close on January 21, Abbott stock traded at $121.14, but plummeted to $112.01 in premarket trading on January 22 at 8:51 AM EST, representing a 7.27% decline. The stock has underperformed the broader market over the past year, gaining just 5.31% compared to the <a href="https://tokenist.com/investing/spx-vs-spy/" rel="dofollow" class="deco-link">S&amp;P 500’s</a> 13.66% return. With a market capitalization of $210.13 billion and a forward <a href="https://tokenist.com/investing/p-e-ratio/" rel="dofollow" class="deco-link">P/E ratio</a> of 21.28, Abbott faces the challenge of restoring investor confidence while executing on its longer-term growth strategy.</p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe> 
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em> <em>All stock prices were quoted at the time of writing.</em></p> 
<p>The post <a rel="nofollow" href="https://tokenist.com/abbott-abt-stock-sinks-despite-eps-match-as-revenue-miss-sparks-selloff/">Abbott (ABT) Stock Sinks Despite EPS Match as Revenue Miss Sparks Selloff</a> appeared first on <a rel="nofollow" href="https://tokenist.com">Tokenist</a>.</p>

Abbott (ABT) Stock Sinks Despite EPS Match as Revenue Miss Sparks Selloff

Table of Contents

Tokenist

Other articles published on Jan 22, 2026

Vitalik Buterin Says Decentralized Social Is How Ethereum Outlives Its Creators

Can HBAR Hit $1? What It Would Take

JasmyChain Completes Mainnet Migration And Enters Production

What to Expect from Bee Network in 2026

Kaisar Network Explained: Earn From Your Idle Hardware

BNB Chain Launches $650k Trenching Season Across Five Trading Platforms

Join our free newsletter for daily crypto updates!